• Rucaparib: From PARP Biology to Assay Design

  2026-08-12

  Rucaparib (AG-014699) is a powerful PARP1 research tool for connecting DNA repair, radiosensitization, and cancer-cell state. This guide translates spliceosome findings in hepatocellular carcinoma into biomarker-aware assay design without overstating clinical evidence.

• Dabigatran etexilate: Direct Thrombin Assay Guide

  2026-08-12

  Build more reproducible thrombin, plasma-clotting, and platelet workflows with Dabigatran etexilate, while accounting for its prodrug chemistry and limited water solubility. This guide connects nanomolar potency data with practical stock preparation, assay selection, troubleshooting, and translational anticoagulant research.

• Praeruptorin A Workflows for Inflammation Research

  2026-08-11

  Praeruptorin A is an angular pyranocoumarin compound suited to mechanism-led studies of ferroptosis, epithelial barrier injury, cardiomyopathy, and tumor invasion. This practical guide connects concentration selection, pathway readouts, dosing logistics, and troubleshooting to help researchers build reproducible preclinical workflows.

• Single-Molecule Screening of Fast-Dissociating Antibodies

  2026-08-11

  Miyoshi and colleagues developed a semi-automated single-molecule TIRF microscopy assay that identifies specific antibodies with rapid dissociation directly from hybridoma cultures. The resulting Fab probes supported multiplexed super-resolution imaging and revealed rapid espin turnover within the dense, long-lived actin cores of inner-ear stereocilia.

• Dacarbazine Workflows for Cancer Drug Response

  2026-08-10

  Build more informative Dacarbazine assays by separating growth inhibition from actual cell killing. This workflow combines DNA-damage profiling, endpoint-specific controls, and practical troubleshooting for malignant melanoma, Hodgkin lymphoma, and sarcoma models.

• Streptavidin-FITC for LNP Trafficking

  2026-08-09

  A mechanistic and translational perspective on using Streptavidin-FITC to track biotinylated cargo, interpret LNP trafficking, and improve fluorescence-based assay strategy.

• Gut Dysbiosis and Docetaxel Resistance in Prostate Cancer

  2026-08-08

  Zhong et al. connect antibiotic-associated gut dysbiosis with prostate cancer progression and reduced Docetaxel sensitivity through increased gut permeability, intratumoral lipopolysaccharide, and activation of the NF-κB–IL6–STAT3 axis. The study combines mouse models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic assays, and patient samples to identify Proteobacteria enrichment as a candidate marker of advanced disease.

• Penicillin G Sodium: Applied Research Workflows

  2026-08-07

  Penicillin G Sodium is a natural penicillin antibiotic for controlled Gram-positive selection, infection-model benchmarking, and contamination management—not a universal cell-culture additive. This guide connects its bacterial cell wall mechanism with barrier-inflammation workflows while separating product-supported evidence from practical assay recommendations.

• Cy5 TSA Fluorescence System Kit: Signal Amplification in IHC

  2026-08-07

  The Cy5 TSA Fluorescence System Kit delivers robust, HRP-catalyzed tyramide deposition for 100-fold signal amplification in immunohistochemistry and in situ hybridization. This kit enables sensitive detection of low-abundance targets and reduces reagent consumption, with fast, covalent Cy5 labeling for high-resolution imaging.

• ST3GAL1-Mediated Sialylation Drives Fusobacterium Adhesion i

  2026-08-06

  This study identifies ST3GAL1-driven sialylation as a key mechanism enhancing the adhesion and colonization of Fusobacterium nucleatum in colorectal cancer cells. The findings deepen our understanding of host-microbe interactions in tumor microenvironments and highlight sialylated glycans as potential targets for investigating microbial persistence in cancer.

• Solving Assay Challenges with EZ Cap™ Cy5 Firefly Luciferase

  2026-08-06

  Discover how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) addresses persistent laboratory challenges in mRNA delivery, cell viability, and bioluminescence assays. This scenario-driven guide offers validated, evidence-based insights for optimizing workflow sensitivity and reliability using APExBIO’s advanced dual-reporter mRNA.

• Scenario-Driven Workflows with Bromodomain Inhibitor, (+)-JQ

  2026-08-05

  This article guides researchers through real laboratory challenges in apoptosis, viability, and inflammation assays, demonstrating how Bromodomain Inhibitor, (+)-JQ1 (SKU A1910) from APExBIO delivers data-backed, reproducible solutions. Each section addresses practical experimental bottlenecks, protocol optimization, and vendor reliability, offering scenario-based insights for biomedical scientists.

• Fludarabine as a DNA Synthesis Inhibitor: Redefining Immuno-

  2026-08-05

  Explore how Fludarabine, a potent DNA synthesis inhibitor, uniquely enables advanced immuno-oncology research. This article delves into assay design, mechanistic synergy with T cell therapies, and practical guidance for optimizing experimental outcomes.

• BIBP 3226 Trifluoroacetate: Workflow Advances in NPY/NPFF Re

  2026-08-04

  BIBP 3226 trifluoroacetate empowers precise dissection of neuropeptide Y and FF receptor pathways, driving innovation in anxiety, analgesia, and cardiovascular research. With robust protocol versatility and proven high-affinity antagonism, it stands as a cornerstone for reproducible NPY/NPFF system studies.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-08-04

  Schwartz's dissertation introduces a nuanced framework for evaluating anti-cancer drug responses, distinguishing between growth inhibition and cell death in vitro. This approach clarifies drug action profiles, crucial for optimizing antineoplastic chemotherapy drug development and translational cancer research.

15196 records 1/1014 page Next 12345 下5页 Last page